Table 2.

Comparison of cerebral SVD in Meth versus propensity score-matched control group after removing the patients with stimulant use for ADHD.

Variables	Meth group	PS-matched control group	p
N	55	55
Age	55 ± 10	55 ± 10	0.978
Male (%)	45 (81.8)	38 (69.1)	0.183
Race			0.006
White	43 (78.2)	25 (45.5)
Hispanic	6 (10.9)	4 (7.3)
Black	3 (5.5)	11 (20)
Asian	2 (3.6)	10 (18.2)
Other	1 (1.8)	5 (9.1)
Hypertension	36 (65.5)	31 (56.4)	0.329
Diabetes	19 (34.5)	20 (36.4)	0.329
Hyperlipidemia	15 (27.3)	20 (36.4)	0.306
Obesity	10 (18.2)	13 (23.6)	0.482
NIHSS	5 (6)	4 (6)	0.245
Cerebral SVD
WMHs	3 (3)	2 (3)	< 0.001
Lacunes	2 (4)	1 (2)	0.032
Microbleeds	2 (4)	0 (4)	0.369
Enlarged perivascular space	1 (1)	1 (1)	0.346
Total burden	2 (1)	2 (1)	0.006
Baseline SBP	159 ± 31	170 ± 39	0.083
Baseline DBP	97 ± 20	95 ± 20	0.573
SBP at discharge	130 ± 17	133 ± 20	0.411
DBP at discharge	77 ± 13	76 ± 13	0.703
Reduction in SBP	27 ± 27	40 ± 30	0.038
Reduction in DBP	19 ± 21	20 ± 20	0.915
Numbers of Antihypertensives	3 (3)	2 (3)	0.790

The Meth group in this analysis excluded patients with history of stimulant use for ADHD. Propensity score-matched patients from the Non-Meth group was used as control.

Data are expressed as n (%), mean ± SD, or median (interquartile range, IQR).

ADHD attention deficit hyperactivity disorder, DBP diastolic blood pressure, NIHSS National Institutes of Health Stroke Scale, PS propensity score, SBP systolic blood pressure, WMHs white matter hyperdensities.

Significant are in value [bold].